Digestery
Longevity supplements › Resveratrol and Aging › Studies

Randomized trial · measured other health measures

12-week trial in 60 older adults with walking trouble found mixed results with resveratrol

Harper and colleagues · Experimental gerontology · 2021

Original title: Resveratrol and exercise combined to treat functional limitations in late life: A pilot randomized controlled trial.

Under review. A person has not yet checked this summary against the paper. It is written from the PubMed abstract. Until a person checks it, search engines are asked not to list this page.

What the study found

Mixed

Side effects were similar across groups. Six-minute walk gain was 9.45 m with placebo, 22.9 m on 500 mg and 33.1 m on 1000 mg. Gait speed changed little (-0.04 to 0.04 m/s).

The study at a glance

Type of study
Randomized trial
Who or what was studied
60 people · Community-living adults, average age 71.8, with trouble walking or moving
What was tested
12 weeks of exercise plus placebo, or plus resveratrol 500 mg a day, or plus 1000 mg a day
What it measured
Several kinds of outcomes
Daily amount
1000 mg a day
How long
12 weeks
Who has a stake
Company stake
One author is a consultant for Reserveage Organics, which supplied the resveratrol and placebo pills.
Journal
Experimental gerontology, 2021
Source
PubMed record 33068691. This page is based on the abstract only.

How much this study counts

  • ✓Randomized: people were put into groups by chance, so the groups start out alike.
  • ✓Compared with a placebo, a dummy treatment.
  • •Medium size: 60 people.
  • •Lasted 12 weeks.
  • •Measured several kinds of outcomes.
  • –Company stake: One author is a consultant for Reserveage Organics, which supplied the resveratrol and placebo pills.
  • •Summarized from the PubMed abstract only. The full paper may hold details the abstract leaves out.

✓ Strength– Limit• Note

These points come from fixed rules about the type of study, its size and length, what it measured, and who has a stake. Every study on Digestery gets the same rules.

Where this study sits

Each dot is one on-topic paper on this question. Steps near the top answer the question more directly.

↑ Stronger evidence

  1. Trials in people: aging and age-related decline

    3

    1 benefit, 1 mixed, 1 no difference

  2. Trials in people: other measures

    3

    1 benefit, 1 mixed, 1 harm

    ↑ This study is the ringed dot

  3. Trials in people: lab tests or safety

    7

    4 benefit, 2 mixed, 1 no difference

  4. Population studies

    1

    1 benefit

  5. Blood levels and genes

    1

    1 no difference

  6. Animals

    1

    1 benefit

↓ Weaker evidence

  • Points to benefit
  • Mixed
  • No difference
  • No direction
  • Points to harm

How it fits with the other research

The short answer to “Does resveratrol slow aging?”

Not shown in people.

Confidence: very low. Based on 22 on-topic papers.

Read the full answer

Of the other 2 papers on the same step: 1 benefit, 1 harm. This one found mixed.

Other papers on the same step

See all 22 studies on this question

How this page was made

Label

First read of the abstract
Claude Sonnet
Independent second read
Claude Haiku
Differences settled
The two reads differed. The reviewer checked the abstract and kept the first read. Claude Opus 5.5.
Headline
Claude Sonnet, from the checked study record. A script checked its numbers and wording.
Numbers
Checked against the abstract by a script
“How much this study counts”
Fixed rules, the same for every study
Source check by a person
Not yet. Required before search engines may list this page.

Spot an error? Email a flag with a link to your source, or use the form on the question page.